

Anti-CD55 (Extracellular region) Antibody
Catalog # AN1696**Specification**

Anti-CD55 (Extracellular region) Antibody - Product Information

Application	WB, IHC
Primary Accession	P08174
Host	Mouse
Clonality	Mouse Monoclonal
Isotype	IgG2a
Calculated MW	41400

Anti-CD55 (Extracellular region) Antibody - Additional Information

Gene ID	1604
Other Names	
Complement decay-accelerating factor, DAF, CD_antigen, CD55, CR	

Target/Specificity

CD55, also known as Decay-accelerating factor (DAF) is an inhibitor of the complement system, and is broadly expressed in malignant tumours. In cancer, CD55 has been implicated in tumorigenesis, neoangiogenesis, and metastasis. CD55 may decrease complement mediated tumor cell lysis, inhibit tumor apoptosis, and promote invasive cancer cell motility. These roles in cancer may involve binding to the seven-span transmembrane receptor CD97. In neuroblastoma cells, CD55 contributes to growth of colonies and to invasion of cells, but not to stemness. In neuroblastoma cells, CD55 is upregulated in a small population of cells that are HIF-2 α positive. This CD55 positive subpopulation is highly invasive and has low adhesion to fibronectin and collagen. In addition, CD55 expression correlates with poor prognosis in neuroblastoma patients.

Dilution

WB~~1:1000
IHC~~1:100~500

Format

Protein G Purified

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

Anti-CD55 (Extracellular region) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Shipping


Blue Ice

Anti-CD55 (Extracellular region) Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-CD55 (Extracellular region) Antibody - Images



Immunocytochemical labeling of CD55 in paraformaldehyde fixed human MDA-MB-231 breast cancer cells. The cells were labeled with mouse monoclonal anti-CD55 (CM0021). The antibody was detected using goat anti-mouse DyLight® 594.

Anti-CD55 (Extracellular region) Antibody - Background

CD55, also known as Decay-accelerating factor (DAF) is an inhibitor of the complement system, and is broadly expressed in malignant tumours. In cancer, CD55 has been implicated in tumorigenesis, neoangiogenesis, and metastasis. CD55 may decrease complement mediated tumor cell lysis, inhibit tumor apoptosis, and promote invasive cancer cell motility. These roles in cancer may involve binding to the seven-span transmembrane receptor CD97. In neuroblastoma cells, CD55 contributes to growth of colonies and to invasion of cells, but not to stemness. In neuroblastoma cells, CD55 is upregulated in a small population of cells that are HIF-2 α positive. This CD55 positive subpopulation is highly invasive and has low adhesion to fibronectin and collagen. In addition, CD55 expression correlates with poor prognosis in neuroblastoma patients.